The clinical trial, sponsored by Assoc. Prof. Dr. Sabri Hergüner, focuses on an online group-based parent-mediated intervention program for children with Autism Spectrum Disorder (ASD) who experienced significant life disruptions due to the February 2023 earthquake in Turkey. This initiative addresses a critical gap in support for ASD populations post-disaster, potentially positioning the sponsor as a leader in innovative therapeutic approaches for ASD in crisis contexts. The market for ASD interventions is growing, particularly in regions affected by natural disasters, highlighting the need for scalable, accessible solutions. The trial's outcomes could inform future product development and partnerships with educational and therapeutic institutions, enhancing the sponsor's competitive edge in the ASD treatment landscape.